# Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination

> **NCT02475135** · PHASE1 · COMPLETED · sponsor: **Janssen Sciences Ireland UC** · enrollment: 72 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
- **DRUG:** Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
- **DRUG:** Darunavir
- **DRUG:** Emtricitabine/Tenofovir alafenamide (FTC/TAF)
- **DRUG:** Cobicistat
- **OTHER:** High-fat Breakfast
- **OTHER:** Standardized Regular Breakfast

## Key facts

- **NCT ID:** NCT02475135
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-01
- **Primary completion:** 2015-08-14
- **Final completion:** 2015-08-14
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02475135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02475135, "Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02475135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*